You are here: Industry Insights > Bristol-Myers Squibb

News List

Havas Health quietly picks up Bristol-Myers Squibb's media business after Sanofi retention win fiercepharma
August 31, 2017
Havas Health & You quietly noted a media win of the global Bristol-Myers Squibb account in 2Q filings last week.
Pfizer's hunt for new Manhattan HQ lands on snazzy Spiral skyscraper: report fiercepharma
August 28, 2017
Selling Pfizer's old headquarters just got a lot more attractive, according to the Post, which said recent rezoning will allow a much taller building to rise in its place, making the site more valuable.
Upstart Blade nabs Bristol-Myers Squibb research executive as new R&D lead fiercebiotech
August 22, 2017
Nabbing a BMS executive is a big coup for Blade, a small biotech betting big on the NASH space.
Bristol-Myers Squibb nixes 58 marketing jobs as HIV medications near patent cliff fiercepharma
August 10, 2017
Six of the workers set to lose their posts in Bristol-Myers HIV unit live in New Jersey, while 52 work remotely.
Bristol-Myers Squibb to buy IFM Therapeutics for $300m pharmaceutical-technology
August 08, 2017
Bristol-Myers Squibb (BMS) has entered a definitive agreement to purchase all outstanding capital stock of IFM Therapeutics (IFM) for $300m.
Bristol-Myers Squibb and Clovis Oncology announce a broad clinical collaboration worldpharmanews
August 01, 2017
Bristol-Myers Squibb Company and Clovis Oncology, Inc. announced the companies have entered into a clinical collaboration agreement to evaluate the combination of Bristol-Myers Squibb's immunotherapy Opdivo and ...
U.S. Food and Drug Administration expands approval of Yervoy® (ipilimumab) to include pediatric pati worldpharmanews
July 25, 2017
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has expanded the indication for Yervoy ) injection for intravenous ,,,
FDA approves Bristol-Myers Squibb’s Orencia for active psoriatic arthritis pharmaceutical-technology
July 11, 2017
The US Food and Drug Administration (FDA) has approved Bristol-Myers Squibb’s Orencia for the treatment of adult patients with active psoriatic arthritis (PsA).
Phase 3 Study of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint americanpharmaceuticalreview
July 06, 2017
Bristol-Myers Squibb announced a Phase 3 study evaluating Opdivo 3 mg/kg versus Yervoy 10 mg/kg in patients with stage IIIb/c or stage IV melanoma who are at high risk of recurrence following complete surgical resection met its primary endpoint at a plann
Bristol-Myers Squibb Voluntarily Recalls One Lot of Eliquis 5 mg Tablets americanpharmaceuticalreview
June 15, 2017
Bristol-Myers Squibb Company is voluntarily recalling one lot (#HN0063) of Eliquis 5 mg tablets to the consumer level

Previous page 1 2 3 4 5 6 7 8 9 10 Next page